SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

BRIEF-Syros Receives FDA Orphan Drug Designation For SY-5609

BRIEF-Syros Receives FDA Orphan Drug Designation For SY-5609

Reuters · 09/13/2022 16:04
BRIEF-Syros Receives FDA Orphan Drug Designation For SY-5609

- Syros Pharmaceuticals Inc SYRS.O:

  • SYROS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SY-5609 FOR THE TREATMENT OF PANCREATIC CANCER

  • SYROS PHARMACEUTICALS INC- SAFETY AND CLINICAL ACTIVITY DATA FROM SAFETY LEAD-IN PORTION OF TRIAL ARE EXPECTED IN SECOND HALF OF 2022

  • SYROS PHARMA - UNDER CLINICAL SUPPLY DEAL WITH ROCHE, SYROS SUPPLYING SY-5609 FOR COMBINATION DOSING COHORT IN ROCHE'S PHASE 1/1B INTRINSIC TRIAL

Source text for Eikon: ID:

Further company coverage: SYRS.O


((Reuters.Briefs@thomsonreuters.com;))